FINERENONE - AN OVERVIEW

There were no clinically substantial differences during the pharmacokinetics of both midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when used concomitantly with finerenone. Many doses of 40 mg finerenone when-every day experienced no clinically related effect on AUC or Cmax with the BCRP and OATP substrate rosuvastatin.fentanyl tran